Clinical trials: Myeloma Multiple
Venous Thromboembolism, Multiple Myeloma
Apixaban for Primary Prevention of Venous Thromboembolism in Patients With Multiple Myeloma
Patients living with multiple myeloma (MM) have an increased risk of venous thromboembolism (VTE) due to the disease itself and the use of targeted therapies, including immunomodulatory drugs (IMiDs).
- Trial name
- NCT02958969
- Testing
- Apixaban
- Where
- 2 sites in United States
- Volunteers
- 50 people
- Sponsor
- Gregory Piazza
Multiple Myeloma
Melphalan, Prednisone, and Thalidomide or Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma
This randomized phase III trial studies melphalan and prednisone with thalidomide to see how well it works compared to melphalan and prednisone together with lenalidomide in treating patients with newly diagnosed multiple…
- Trial name
- NCT00602641
- Testing
- Laboratory Biomarker Analysis, Lenalidomide, Melphalan
- Where
- 391 sites in United States, Israel
- Volunteers
- 306 people
- Sponsor
- National Cancer Institute (NCI)
Refractory Multiple Myeloma
Dinaciclib in Treating Patients With Relapsed or Refractory Multiple Myeloma
This phase II trial is studying how well giving dinaciclib works in treating patients with relapsed or refractory multiple myeloma.
- Trial name
- NCT01096342
- Testing
- dinaciclib, laboratory biomarker analysis
- Where
- 6 sites in United States, Singapore
- Volunteers
- 16 people
- Sponsor
- National Cancer Institute (NCI)
Non-hodgkins Lymphoma, Hodgkins Lymphoma
Oncaspar/Doxil/Decadron in Patients With Refractory Lymphoid Malignancies
This is an exploratory study to study the efficacy of combination regimen of Oncaspar/Doxil/Decadron (ODD) in patients with refractory lymphoid malignancies.
- Conditions
- Non-hodgkins Lymphoma, Hodgkins Lymphoma, Multiple Myeloma
- Trial name
- NCT00837200
- Testing
- Oncaspar, Doxil, Decadron
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Milton S. Hershey Medical Center
Multiple Myeloma
Radiotherapy With Immunotherapy for Systemic Effect in Myeloma (RISE-M)
Eligible patients have multiple myeloma with measurable disease in the blood and a targetable soft tissue or bony lesion with radiotherapy.
- Trial name
- RISE-M (NCT03634800)
- Testing
- Nivolumab 240mg, Radiation therapy
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Weill Medical College of Cornell University
Multiple Myeloma, Lymphoma, Non-Hodgkin's
AMD3100 (Plerixafor) in Multiple Myeloma (MM) or Non-Hodgkin's Lymphoma (NHL) Patients Predicted to be Unable to Mobilize With G-CSF Alone
This Phase 2 study was designed to assess the safety and hematological activity of AMD3100 (plerixafor) in patients with non-Hodgkin's lymphoma (NHL) or multiple myeloma (MM) who were predicted to be unable to mobilize ≥2*10^6…
- Trial name
- NCT00395967
- Testing
- G-CSF plus plerixafor
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Genzyme, a Sanofi Company
Multiple Myeloma
Bone Effect of Bortezomib in Patients With Relapsed/Refractory Multiple Myeloma
The primary aim of this trial is to determine the effect of a short course (i.e., 3 cycles) of low-dose Bortezomib (Velcade) on bone remodeling and on disease progression.
- Trial name
- NCT01062230
- Testing
- Bortezomib (Velcade)
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- University of Arkansas
Secondary Immunodeficiencies (SID)
Quality Assurance of Secondary Immunodeficiencies (SID) in CLL/MM Patients
Retrospective, representative registry for quality assurance on diagnosis and therapy of secondary immunodeficiencies (SID) in patients with chronic lymphocytic leukemia (CLL) or multiple myeloma (MM)
- Trial name
- QS-SID (NCT04172467)
- Testing
- non-interventional retrospective epidemiological observational study
- Where
- Germany
- Volunteers
- 1,086 people
- Sponsor
- AIO-Studien-gGmbH
Multiple Myeloma, Multiple Myeloma in Relapse
Pembrolizumab for the Treatment of Relapsed or Refractory Multiple Myeloma After Anti-BCMA CAR-T Therapies
This phase II trial tests whether pembrolizumab works to shrink tumors in patients with multiple myeloma whose cancer has come back (relapsed) or did not respond to previous treatment (refractory) with anti-BCMA CAR-T therapies.
- Conditions
- Multiple Myeloma, Multiple Myeloma in Relapse, Multiple Myeloma, Refractory, Recurrent Plasma Cell Myeloma
- Trial name
- NCT05191472
- Testing
- Pembrolizumab
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Alfred Chung, MD
Multiple Myeloma
Administration of Tadalafil in Conjunction With Lenalidomide and Dexamethasone in Patients With Multiple Myeloma
The primary objective of this study is to evaluate the anti-tumor efficacy of tadalafil in combination with Lenalidomide/dexamethasone (Rd) in multiple myeloma.
- Trial name
- NCT01374217
- Testing
- Tadalafil, Lenalidomide, Dexamethasone
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Multiple Myeloma
A Study of the Safety and Efficacy of CNTO 328 and Bortezomib to Bortezomib Alone in Patients With Relapsed or Refractory Multiple Myeloma
The purpose of Part 1 of the study is to determine the safety of the combination of Siltuximab (CNTO 328) and bortezomib (Velcade).
- Trial name
- NCT00401843
- Testing
- Siltuximab, Bortezomib, Dexamethasone
- Where
- 80 sites in United States, Belgium and 16 more
- Volunteers
- 307 people
- Sponsor
- Janssen Research & Development, LLC
Relapsed Multiple Myeloma, Relapsed-Refractory Multiple Myeloma
Study of Melflufen (Melphalan Flufenamide) in Combination With Daratumumab in Relapsed-Refractory Multiple Myeloma
This was a randomized, controlled, open-label, Phase 3 multicenter study which enrolled patients with Relapsed-Refractory Multiple Myeloma (RRMM) who were either double refractory to an Immunomodulatory Drug (IMiD) and a…
- Trial name
- LIGHTHOUSE (NCT04649060)
- Testing
- Melflufen, Dexamethasone, Daratumumab
- Where
- 26 sites in Bulgaria, Czechia and 9 more
- Volunteers
- 54 people
- Sponsor
- Oncopeptides AB
Multiple Myeloma, Plasma Cell Neoplasm
2nd Autologous Stem Cell Transplant in Patients With Persistent/Recurrent (AL) Amyloidosis
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of plasma cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00075608
- Testing
- filgrastim, melphalan, autologous stem cell transplantation
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Boston Medical Center
Multiple Myeloma in Relapse, Multiple Myeloma Progression
Tinostamustine Conditioning and Autologous Stem Cell
Phase 1 The primary objectives of Phase 1 of this study are to: Establish the safety, toxicity, and maximum tolerated dose (MTD) of the tinostamustine conditioning regimen.
- Conditions
- Multiple Myeloma in Relapse, Multiple Myeloma Progression, Multiple Myeloma With Failed Remission
- Trial name
- TITANIUM1 (NCT03687125)
- Testing
- Tinostamustine, Autologous Stem Cell Transplant (ASCT)
- Where
- 12 sites in United States, Norway and 1 more
- Volunteers
- 6 people
- Sponsor
- Mundipharma-EDO GmbH
Acute Myelogenous Leukemia, Lymphoid Leukemia
T-Cell Depleted Allogeneic Stem Cell Transplantation for Patients With Hematologic Malignancies
Objectives: 1. To evaluate disease free survival after Campath 1H-based in vivo T-cell depletion and non-myelo-ablative ablative stem cell transplantation in patients with hematologic malignancies. 2.
- Conditions
- Acute Myelogenous Leukemia, Lymphoid Leukemia, Chronic Myelogenous Leukemia, Malignant Lymphoma
- Trial name
- NCT00683046
- Testing
- Fludarabine, Melphalan, Stem cells
- Where
- United States
- Volunteers
- 204 people
- Sponsor
- University of Chicago
Multiple Myeloma and Plasma Cell Neoplasm
Lenalidomide and Rituximab in Treating Patients With Recurrent and/or Refractory Multiple Myeloma
RATIONALE: Lenalidomide may stop the growth of multiple myeloma by blocking blood flow to the cancer. Monoclonal antibodies, such as rituximab, can block cancer growth in different ways.
- Trial name
- NCT00567229
- Testing
- rituximab, lenalidomide, microarray analysis
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Multiple Myeloma
Carfilzomib and Lenalidomide With Dexamethasone Combination in Newly Diagnosed, Previously Untreated Multiple Myeloma
This study is designed to evaluate the safety and to determine the maximum tolerated dose of carfilzomib + lenalidomide in combination with dexamethasone in newly diagnosed Multiple Myeloma patients who have not received…
- Trial name
- NCT01029054
- Testing
- carfilzomib, lenalidomide plus dexamethasone
- Where
- 4 sites in United States
- Volunteers
- 53 people
- Sponsor
- University of Michigan Rogel Cancer Center
Cancer-related Problem/Condition, Depression
Programmed Environmental Illumination (PEI) of Hospital Rooms to Prevent/Reduce Cancer-Related Fatigue
A sample of 60 patients scheduled for HSCT in the treatment of MM will be recruited in the weeks to months prior to their hospitalization.
- Conditions
- Cancer-related Problem/Condition, Depression, Circadian Rhythm Disorders
- Trial name
- PEI (NCT03198754)
- Testing
- PEI Experimental Light, Comparison Light
- Where
- United States
- Volunteers
- 73 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Relapsed/Refractory, Multiple Myeloma
A Study to Investigate the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of TAK-079 Administered Subcutaneously as a Single Agent in Participants With Relapsed/Refractory (r/r) Multiple Myeloma (MM)
The purpose of this study is to assess the safety and tolerability, maximum tolerated dose (MTD)/recommended phase 2 dose (RP2D) of TAK-079 monotherapy and when combined with a backbone regimen of pomalidomide and dexamethasone…
- Trial name
- NCT03439280
- Testing
- Mezagitamab, Pomalidomide, Dexamethasone
- Where
- 7 sites in United States
- Volunteers
- 50 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Multiple Myeloma
Determining the Feasibility of MLN9708 as Maintenance After Allogeneic Stem Cell Transplant for Multiple Myeloma
The purpose of the study is to determine the safety of MLN9708 as maintenance therapy following allogeneic stem cell transplant in patients with multiple myeloma.
- Trial name
- NCT02168101
- Testing
- MLN9708
- Where
- 4 sites in United States
- Volunteers
- 9 people
- Sponsor
- SCRI Development Innovations, LLC